At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating Carboplatin, Cisplatin, and 7 other interventions for Head and Neck Squamous Cell Carcinoma and 2 related conditions. Completed, enrolled 24 participants across 5 sites.
Detailed Summary
This partially randomized phase I/II trial studies the side effects and best dose of veliparib when given together with combination chemotherapy and to see how well they work in treating patients with stage IV head and neck cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective when given with or without veliparib in treating head and neck cancer.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given PO
Correlative studies
Given IV
Given PO
Undergo radiation therapy
Given PO